Nancy Freda Smith, a director at Tempest Therapeutics, Inc., has reported a stock option transaction involving 25,000 shares. This event is significant as it illustrates the ongoing commitment of company executives to their roles and the potential for future growth within the organization.
Background
Tempest Therapeutics, Inc. operates in the pharmaceutical preparations sector, focusing on innovative treatments and therapies. The company is incorporated in Delaware and has its fiscal year ending on December 31. Recent filings include a Form 4 and a Form 3, both filed on October 2, 2026, indicating active reporting by its directors and executives.
What the Filing Says
According to the filing, Smith acquired 25,000 stock options at an exercise price of $1.00 per share on September 22, 2026. The filing notes, "The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service." This structured vesting schedule emphasizes the importance of ongoing commitment from Smith to the company.
Impact
This transaction may affect shareholders and potential investors in Tempest Therapeutics, as it reflects the confidence of leadership in the company's future. The pharmaceutical preparations sector is known for its volatility, and executive transactions can influence market perceptions and investor sentiment.
What's Next
The filing does not say what happens next.